Skip to content
Study details
Enrolling now

A Master Protocol (LY900023) for Children and Young Adults With Cancer

Eli Lilly and Company
NCT IDNCT05999994ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

105

Study length

about 7.4 years

Ages

1–39

Locations

29 sites in AL, AZ, CA +18

What this study is about

This trial is testing several drugs to treat cancer in children and young adults. The goal of this master protocol is to improve how research sites carry out clinical trials by providing a common research plan. New studies will be added as new drugs are developed against different cancers.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Abemaciclib
  • 2.Take Cyclophosphamide
  • 3.Take Docetaxel
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

abemaciclib, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), docetaxel, gemcitabine, irinotecan, ramucirumab, temozolomide, vinorelbine

Drug routes

oral (Oral Tablet), infusion, injection (Injection), injection, intravenous